source
- Supernus and Individor to merge, creating $2 billion brain-drug companySupernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
- Supernus and Indivior announce all-stock merger to create CNS-focused drugmakerSupernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses. The new company will be dedicated to developing treatments for central…